Sector News

Emerging markets still beat elsewhere for Big Pharma growth, with AstraZeneca in the lead

June 23, 2015
Life sciences
Growth in emerging markets may be slowing, but pharma sales there are still outpacing those everywhere else. And if recent numbers are any indication, AstraZeneca is topping its rivals for emerging markets expansion.
 
That’s the message in a new report from Bernstein & Co. analysts, who looked at sales growth for 7 Big Pharma companies over the past few years–and the first quarter of 2015 in particular.
 
AstraZeneca’s sales in the developing world jumped by 14% over the last four quarters–four percentage points ahead of next-place companies Pfizer and Sanofi–and beat all comers quarter-by-quarter as well. Much of that growth came in China, which now accounts for almost half of AstraZeneca’s emerging markets sales.
 
Slowest growth? That would be Merck & Co., with 6% over the last four quarters, and Eli Lilly & Co., with 4% for Q1 alone. No word on GlaxoSmithKline, which had suffered after a bribery scandal in China; the U.K.-based drugmaker stopped breaking out emerging markets sales at the end of 2014. Bristol-Myers Squibb doesn’t specify its emerging markets sales either.
 
Overall, the 7 companies averaged 8.8% growth in emerging markets for the first quarter and 9.4% over the past four. That’s certainly less than the double-digit growth rates of several years ago, given increasing pricing pressures in pharma and an economic slowdown overall. But compared with growth elsewhere, it’s a windfall. In the U.S., these companies’ sales slipped by 1.3% over the past four quarters and grew just 2% in Q1. Other international markets suffered even more, with 2% slippage for the four-quarter period and 3.9% for Q1.
 
Which drugmakers depend most on emerging markets? Sanofi reaps the biggest share of its revenue–32%–in those countries, with AstraZeneca (27%) and Novartis  (26%) close behind. It should be noted, however, that AstraZeneca’s big share partly depends on the fact that its U.S. sales have been dropping, thanks to Nexium generics. Pfizer and Roche each count 24% of their sales in the developing world, while Eli Lilly relies the least on emerging markets, with 16% of its sales there.
 
Despite the slowdown in emerging markets, investing there still makes sense, Bernstein’s Tim Anderson said in the investor note, particularly as a tactic for long-term growth in branded sales. “Despite being a lower margin business (margins are about half that of developed markets), multinational drug companies are more than covering their costs,” Anderson says, “and their collective commercial presence in EMs sets the stage for the longer-term, gradual, yet inevitable shift from older off-patent medicines to more lucrative, novel, on-patent medicines.”
 
By Tracy Staton
 

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach